Published in Elife on February 06, 2017
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52
NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR (1995) 93.94
Features and development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 89.46
Java Treeview--extensible visualization of microarray data. Bioinformatics (2004) 24.12
Open source clustering software. Bioinformatics (2004) 23.17
Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39
The conformational plasticity of protein kinases. Cell (2002) 11.21
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet (1999) 5.29
Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci (2002) 5.28
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 5.17
Utilization of site-directed spin labeling and high-resolution heteronuclear nuclear magnetic resonance for global fold determination of large proteins with limited nuclear overhauser effect data. Biochemistry (2000) 4.52
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol (2005) 3.73
Protein tyrosine kinase structure and function. Annu Rev Biochem (2000) 3.62
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet (1997) 3.11
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene (2007) 2.83
Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell (1996) 2.75
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell (2007) 2.70
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell (2004) 2.64
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood (2009) 2.51
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A (2005) 2.38
A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood (1997) 2.31
FGFR activation in skeletal disorders: too much of a good thing. Trends Genet (1997) 2.30
A TROSY CPMG sequence for characterizing chemical exchange in large proteins. J Biomol NMR (1999) 2.25
Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat (1999) 2.24
Ile, Leu, and Val methyl assignments of the 723-residue malate synthase G using a new labeling strategy and novel NMR methods. J Am Chem Soc (2003) 2.20
Observing biological dynamics at atomic resolution using NMR. Trends Biochem Sci (2009) 2.19
Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev (2005) 2.10
Allosteric cooperativity in protein kinase A. Proc Natl Acad Sci U S A (2008) 1.99
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol (2001) 1.94
[20] Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol (1997) 1.92
Measurement of slow (micros-ms) time scale dynamics in protein side chains by (15)N relaxation dispersion NMR spectroscopy: application to Asn and Gln residues in a cavity mutant of T4 lysozyme. J Am Chem Soc (2001) 1.91
Mapping allostery through the covariance analysis of NMR chemical shifts. Proc Natl Acad Sci U S A (2011) 1.89
Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am J Hum Genet (2002) 1.88
The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell (2009) 1.68
Probing slow dynamics in high molecular weight proteins by methyl-TROSY NMR spectroscopy: application to a 723-residue enzyme. J Am Chem Soc (2004) 1.65
NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew Chem Int Ed Engl (2006) 1.61
Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet (2000) 1.58
A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proc Natl Acad Sci U S A (2008) 1.25
Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. J Med Genet (2000) 1.22
Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proc Natl Acad Sci U S A (2010) 1.10
A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem (2015) 1.04
A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online. Hum Mutat (1998) 1.01
Autoinhibitory mechanisms in receptor tyrosine kinases. Front Biosci (2002) 1.01
Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia. Hum Mutat (1998) 0.99
Cracking the molecular origin of intrinsic tyrosine kinase activity through analysis of pathogenic gain-of-function mutations. Cell Rep (2013) 0.93
A tool set to map allosteric networks through the NMR chemical shift covariance analysis. Sci Rep (2014) 0.93
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia (2013) 0.90
A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor. J Biol Chem (2011) 0.89
Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia. Acta Paediatr (2000) 0.88
A further mutation of the FGFR2 tyrosine kinase domain in mild Crouzon syndrome. Eur J Hum Genet (2005) 0.85
DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors. ACS Chem Biol (2014) 0.84
Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 mutation. Structure (2013) 0.84
Thanatophoric dysplasia caused by double missense FGFR3 mutations. Am J Med Genet A (2009) 0.83
Familial scaphocephaly syndrome caused by a novel mutation in the FGFR2 tyrosine kinase domain. J Med Genet (2005) 0.82
Characterization of tyrosine kinase I domain c-kit gene mutation Asn655Lys newly found in primary jejunal gastrointestinal stromal tumor. Am J Gastroenterol (2007) 0.82
Novel mutation in the tyrosine kinase domain of FGFR2 in a patient with Pfeiffer syndrome. Am J Med Genet A (2004) 0.81
A novel variant of FGFR3 causes proportionate short stature. Eur J Endocrinol (2015) 0.79
Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase Cγ. Mol Cell (2015) 0.77
A novel FGFR2 mutation in tyrosine kinase II domain, L617F, in Crouzon syndrome. J Cell Biochem (2014) 0.76
A novel mutation in FGFR2. Am J Med Genet A (2014) 0.76